A quick and simple method for estimating 25-hydroxyvitamin D is described. It involves dichloromethane extraction followed by competitive protein-binding assay without chromatography. This assay can be performed on 100 iLl of serum and enables 50 samples to be estimated in one working day. The simplicity, speed, and sample size of this method make it very suitable for use in a routine clinical biochemistry laboratory. It is particularly useful when calcium disorders secondary to abnormalities in vitamin D intake and metabolism are suspected.
methane were redistilled before use. Phosphate buffer 0'05 M, pH 7,5, was prepared by mixing 0·05 M Na2HP04 (7'098 g/I) with 0'05 M NaH2P04.2H20 (7'8 gil) in the ratio 640: 160 ml. Barbitone buffer (pH 7'9) consisted of sodium barbitone 2'943 g, anhydrous sodium acetate ] '943 g, sodium chloride 15'3 g, ]900ml distilled water, and 57 ml 0·1 M HCI.
Triton X ]00 (Scintillation Grade, Koch Light) was diluted] :20 in phosphate buffer. BINDING PROTEIN 25-0HD binding protein was prepared from normal rat kidneys (McLaughlin et al., ] 974; Stamp et al., ] 976) . Previous experiments have shown no significant difference in binding to aH 25-0HDa between a binding protein prepared from normal rat kidneys compared to that obtained from rachitic rat kidneys or rachitic rat serum. These findings have been confirmed by Bouillon et al. (1976) .
Kidneys were obtained from 24 male albino Wistar rats weighing approximately 200 g (Anglia Laboratories, Huntingdon) that had been maintained on a normal diet. The kidneys were cleaned of fat, sliced, and put on ice. The tissue was then homogenised for ] minute in phosphate buffer (0,05 M, pH 7,5, 10-25%weight of tissue/vel. buffer) at 5°C. The homogenate was centrifuged at 1500 g for 15 minutes at 5°C and the resultant supernatant was decanted. This was recentrifuged at 105 000 g for 1 hour (5°C), and the clear, postmicrosomal supernatant fluid containing the 25-hydroxyvitamin 106
Recent advances in knowledge of the metabolism of vitamin D (Kodicek, 1974) have established the clinical need for assays of this vitamin and its metabolites. Measurements of the major circulating form of vitamin D, 25-hydroxyvitamin D (25-0HD), are readily available (Haddad and Chyu, ]971; McLaughlin et al.,  ]974). However, these assays are laborious, necessitating extraction and chromatographic and protein-binding steps in addition to requiring comparatively large volumes of serum.
These disadvantages have been reduced in the following way: the assay sensitivity has been increased using tritiated 25-hydroxycholecalciferol with high specific activity, the extraction step has been simplified, and chromatography has been omitted, allowing larger numbers of samples to be accommodated in one assay.
This report describes a simple, quick assay for 25-OHD. (The designation 25-0HD includes, as suggested by Morris and Peacock (1976) , 25-0HDa, 25-0HD2, and 24,25(OHhDa.) The procedure can be performed on ]00 iLl of serum and can easily cope with up to 50 samples in one working day.
Material and methods

STEROIDS
The following unlabelled steroids were used. Cholesterol, 7-dehydrocholesterol, ergocalciferol and cholecalciferol (Sigma), 25-hydroxycholecalciferol (25-0HDa) (Phillips Duphar), 25-hydroxyergocalciferol (25-0HD2) (Upjohn Company, by courtesy of Dr John Babcock), ], 24, , and ] ,24,25-trihydroxycholecalciferol (1,24,25(OHhDa) (Hoffmann-La Roche Inc, by courtesy of Dr M. Uskokovic). aH 25-0HDa was generously supplied by the Radiochemical Centre, Amersham (76 Ci/rnmol, Dr D. C. Warrell) and Hoffman-La Roche Inc (30 Ci/rnrnol, Dr O. N. Miller). D binding protein was separated off and stored in aliquots in stoppered glass vials at -20°C.
Dilution curves were set up to establish the concentration of binding protein that gave binding to 3H 25-hydroxycholecalciferol of approximately 50 %.
SEPARATION PROCEDURE
The protein-bound and free steroids were separated by dextran-coated charcoal. Dextran T40 (Pharmacia, Great Britain, Ltd) 0'5 % in barbitone buffer was mixed with an equal volume of 10% Charcoal (Norit OL, Hopkin and Williams Ltd) in barbitone buffer. The solution (from which the fines were not removed) was kept at 4°C and stirred while being added to the assay tubes with a wide-bore glass pipette.
SCINTILLATION FLUID
A mixture of 667 ml toluene, 333 ml Triton X-loo (undiluted), 5·5 g 2,5-diphenyloxazole (PPO), and 0'1 gp-bis [2-(5-phenyloxazolyl)]-benzene (POPOP) wasused.
PREPARATION OF SERUM SAMPLES
Samples of venous blood were collected into plain tubes and left to clot at room temperature. The serum was separated within 4 hours of collection and stored at -20°C in glass bottles until assayed.
Immediately before assay the serum was thawed, and 100 iLl was pipetted into a Quickfit test tube (MF 24{1); 10 iLl of sH 25-0HDs was added, and the serum was mixed and left to stand in the dark for 30 minutes; 5 ml of dichloromethane :methanol (92:8) was added to each tube, and the tubes were shaken horizontally on a mechanical shaker (Griffin Silent Shaker) for 8 minutes. This method has a similar efficiency to ether extraction and is much safer to use in the laboratory.
The tubes were centrifuged for 4 minutes at 500 g, and two portions of the dichloromethane extract were removed, 500 iLl being used for the assay and 1000 iLl to assess extraction recovery. The latter was evaporated under nitrogen in a scintillation vial. Scintillation fluid was added and the counts obtained were expressed as a percentage of those obtained with 10 iLl of the°H 25-0HDs added originally. ASSAY Methanol-washed glass assay tubes (2 x i in) were used, all estimations being performed in duplicate. Tubes containing standard amounts of 25-0HDs (50, 100, 150, 200, 300, 400, 600, 800 , and 1000 pg) were prepared from serial dilutions of a standard solution of 10 ng{ml in ethanol. Subsequently, 500 iLl of the dichloromethane extracts of samples to be assayed were pipetted into additional assay tubes. The standards and extracts were then evaporated under nitrogen, and 20 iLl (15 pg) of 3H 25-0HDs was added to all tubes. After mixing, 500 iLl of normal rat kidney binding protein diluted 1:500 in phosphate buffer was added, and the tubes were incubated for I hour at room temperature. They were cooled in an ice waterbath for 10 minutes and 20 iLl of I :20 Triton X-loo was added with mixing to act as a solubilising agent. Experiments showed that the addition of Triton X-loo at an earlier stage in the assay procedure increased the non-specific binding. Separation of the bound and free fractions was performed by the addition of 250 fLl of dextran-coated charcoal to each tube. After mixing, the tubes were centrifuged at 4°C for 20 minutes (830 g); 500 fLl of the supernatant was added to 5 ml of scintillation fluid and the radioactivity was counted in a Nuclear Chicago {j-counter. Total activity, sample total activity, sample blank, and assay blank tubes were also prepared and assayed as in Table I . A standard curve plotting % 3H 25-0HD3 bound to binding protein against standard amounts of 25-0HDa, was then drawn. The values for the samples were read from the standard curve.
To obtain the results in ng per ml of serum it is necessary to multiply this reading by 100 to account for the volume of serum extracted and the amount of extract assayed. 
Results
STANDARD CURVE
The standard curve obtained is shown in Figure I . The lower limit of sensitivity of the assay, defined as 2 standard deviations of 20 repl icate determinations, was 15 pg.
PRECISION
The intra-and inter-assay coefficients of variation using serum pools of different values are shown in Table 2 . 6·4. Subsequently, increasing amounts of unlabelled 25-0HD3 were added to sera of known 25-0HD value, and the recovery of 25-0HD3 was determined by assay. The recovery assays were performed either immediately after adding the unlabelled steroid or two weeks after the steroid had been added to the serum. When 5, 10, 20, 30, and 40 ng of 25-0HD3 was added to I ml of serum, the mean amount recovered was I ()()/~, 101 %, I ()()'5 %, 99 %, and 92 % respectively. In addition, serum from a patient who had been treated with high doses of cholecalciferol and was known to have high values of serum 25-0HD was serially diluted and assayed. Comparison of the values obtained with the standard curve showed good linearity.
SPECIFrCITY
Cross reaction of the binding protein with cholecalciferol and its metabolites and related compounds is shown in Figure 2 . 50 % displacement from zero binding was produced by > I fLg per tube of cholesterol, 7 dehydrocholesterol, ergocalciferol, and cholecalciferol, > 10 ng/tube of I,25-(OH )2D3 and 1,24,25-(OH)3Da, 0·375 rig/tube of both 2.5-0HD2 and 25-0HD3, and 0·3 ngjtube of 24,25-(OHhDa. The cross reaction values for 25-0HD2 have been omitted from Fig. 2 for the sake of clarity. All values obtained using this binding protein, therefore, include the measurement of 25-0HD3, 25-0HD2, and 24,25-(OHl2D3 and are known as 25-0HD in accordance with previous usage (Morris and Peacock, 1976) .
COMPARISON WITH PREVIOUS METHOD
Our previous competitive protein binding method (McLaughlin et al., 1974) in routine use in our laboratory for four years has been compared with the method described above. Forty-five serum samples were assayed by both methods and the correlation coefficient (r) was 0·97 (see Fig. 3 ).
It was expected that with our new method, References VALUES ON CLINICAL SAMPLES We have not yet been able to obtain serial samples from normal subjects throughout the year to establish a fresh seasonally adjusted normal range for this assay. However, because of the close correlation of results between this assay and our previous one (McLaughlin et al., 1974) , the normal range for the latter has been used for this assay. Normal values (mean ± 1 SD) for this assay are therefore taken as: December, 24 ± 8 /Lgjl; March, 17 ± 6/Lg/l; June, 30 ± 11 /Lg/I; and September, 34 ± 9 p.g/1. The assay described has been used to study the 25-0HD values in a group of 92 unselected mothers within the first three days after delivery in February. A wide range of values was obtained, the lowest being in the sera from Asian mothers (Fairney et al., 1977) .
The method described has been used to assay up to 50 serum samples at one time without any significant drift in the results of the control values.
In order to establish a practical method for measuring vitamin D status in a diagnostic service laboratory, we have adapted our previously documented 25-0HD assay (McLaughlin et al., 1974) to suit this purpose. The method described in this paper is simple, requires small samples, and is quicker than most other methods. This assay lends itself to the estimation of 25-0HD on capillary blood samples collected from children and is suitable for automation. Like many other competitive protein binding assays for 25-0HD the method described has limitations of specificity. The binding protein used is known to cross react with 25-0HD3, 25-0HD2, and 24,25-(OH)2Da. However, clinical experience with this assay has shown that high and low values obtained correlate well with clinical diagnoses of hypervitaminosis D and osteomalacia respectively. We therefore feel that this method is so useful clinically as easily to outweigh any criticisms of specificity. Fig. 3 Comparison of previously established method (method I) with micromethod described (method 2); values are plotted in ngjml25-hydroxyvitamin D tljuivalents and the regression line is shown.
omission of the chromatographic separation for 24,2S-(OHhD3 from 2S-0HD3 would give higher values than the previous method. We are unable to explain why this is not the case. There is still disagreement about the levels of 24,25-(OH)2Da in normal serum but some published methods yield results that give a mean value as little as 1'63 /Lg/l (Taylor, 1977) .
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